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Abstract
Background Plaque psoriasis is a common, chronic and relapsing inﬂammatory skin disease clinically characterized
by erythema and scaling desquamation. As over 90% of psoriasis patients beneﬁt from topical therapies, local treatments continue to play an eminent role in management strategies. One such topical treatment is the ﬁxed dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP).
Objectives Pooled analysis of two different phase 3 clinical trails to compare superiority regarding efﬁcacy, safety and
quality of life (QoL) between CAL/BDP PAD-cream and CAL/BDP TS.
Methods The data from two phase 3, multicentre, randomized, investigator-blind, active and vehicle-controlled trials
enrolling patients with psoriasis were pooled and analysed. Investigational products included a CAL/BDP cream based
on PADTM Technology (PAD-cream) designed for high skin penetration and increased patient preference, an active control (marketed CAL/BDP topical suspension/gel, in the following abbreviated as CAL/BDP TS) and cream vehicle, which
were applied once daily for 8 weeks.
Results Efﬁcacy and safety of the novel CAL/BDP PAD-cream formulation for the topical treatment of psoriasis
demonstrated superiority for all efﬁcacy end points after 8 weeks of treatment. PGA treatment success for CAL/BDP
PAD-cream (43.2%) was greater than CAL/BDP TS (31.9%; P < 0.0001), the mean per cent reduction in mPASI for CAL/
BDP PAD-cream was 64.6% compared to 56.4% for CAL/BDP TS (P < 0.0001) and DLQI 0/1 was obtained by 43.8% in
the CAL/BDP PAD-cream group versus 34.2% in the CAL/BDP TS group (P = 0.0005). There was no adverse drug reaction reported with a frequency of >1%, associated with the CAL/BDP PAD-cream.
Conclusions The novel ﬁxed dose combination CAL/BDP PAD-cream offers greater efﬁcacy, superior patient QoL and
equivalent favourable safety for the topical treatment of psoriasis, in comparison to the currently available topical suspension/gel.
Received: 21 May 2021; Accepted: 2 September 2021
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Introduction
This manuscript relates to two phase 3 studies, with the
clinicaltrials.gov identiﬁers: NCT03308799 and
NCT03802344.
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Plaque psoriasis is a common, chronic and relapsing inflammatory skin disorder. The prevalence of diagnosed psoriasis is
approximately 3% in the USA,1 and between 2% and 3% in
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Europe.2 Clinically, psoriasis is characterized by erythema and
scaling desquamation that most frequently appears on the scalp,
elbows and/or knees; however, any area of the body can be
affected.3 While the armamentarium of different immunological
targets for moderate-to-severe psoriasis has recently been
expanding, topical steroid-based therapies still continue to play
an eminent role in the majority of treatment for mild-tomoderate disease.4 Most frequently prescribed topical treatment
for adults is a fixed dose combination of calcipotriene (CAL;
Vitamin D analogue) and betamethasone dipropionate (BDP;
glucocorticoid steroid), which is recommended by European,
Canadian and American psoriatic societies as first-line treatment
in mild-to-moderate psoriasis.5–8The efficacy and safety of topical formulations containing fixed dose combinations of CAL
and BDP has been shown in various clinical trials for more than
20 years.9–13 However, the combination of CAL/BDP is not
long-term stable in aqueous environments, as CAL requires basic
conditions to maintain stability and BDP requires acidic conditions.13 Therefore, currently marketed CAL/BDP fixed combinations are restricted to non-aqueous oil- or paraffin-based
formulations (e.g. ointment, topical suspension (TS)/gel or
foam)14 that cause a greasy or sticky feeling that many patients
do not like.15 Patients prefer a topical formulation that dries
quickly, without the sticky or greasy properties that affects skin/
hair/clothing.16 In a large international survey of non-adherence
to topical psoriasis treatment, 73% of patients did not adhere to
their topical treatment mainly because of product greasiness.15
Thus, there is a need for a CAL/BDP fixed dose combination
product that has high efficacy and is more patient friendly than
current formulations. Such product could lead to increased
adherence to treatment; a crucial aspect of any therapy for
chronic conditions such as psoriasis.5,16
CAL/BDP PAD cream (marketed under the brand name
Wynzoraâ Cream) is a fixed dose combination of CAL and BDP
formulated using the PADTM Technology. PADTM Technology
formulations are oil-in-water dispersions but, in contrast to conventional emulsions, the PADTM Technology droplets have relatively high robustness against coalescence and maintain their
physical-chemical stability without needing a large excess of surfactant in the external phase. This high robustness is based on a
multimolecular shell structure that limits any chemical interaction between active molecules solubilized in the internal oil
phase with water molecules in the external phase. PADTM Technology formulations are therefore characterized by having a very
low level of surfactants compared to conventional emulsions
and the physical-chemical robustness enables formulation of
fully solubilized CAL and BDP, even in the presence of water,
which otherwise would lead to significant degradation of the
two active ingredients (Figure 1).
Data from two head-to-head phase 3 trials with essentially
similar inclusion criteria have been pooled to increase the precision of estimates of the efficacy and safety profile of CAL/BDP
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Figure 1 Schematic Structure of a PADTM Technology oil-in-water
droplet. Multimolecular layer of organized surfactant, oil and water
forms robust structure around oil droplets, limiting water contact
and thereby protecting active ingredients in the oil phase against
hydrolysis. PADTM Technology oil-in-water dispersions can form
with just a low level of surfactant in the water and oil phases, in
contrast to conventional emulsions that require a large excess of
surfactant in the water phase to maintain physical stability.

PAD-cream. Both studies were randomized, multicentre,
parallel-group and investigator-blinded studies comparing CAL/
BDP PAD-cream to the active comparator [CAL/BDP gel/topical
suspension (CAL/BDP TS)] and vehicle cream (CAL/BDP PADcream without active ingredients).

Methods
Trial design

In summary, two prospective, investigational, investigator-blind,
vehicle and active- controlled, parallel-group, three-arm, randomized, phase 3 trials were conducted at multiple sites in the
United States of America (MC2-01-C2) and the European
Union (MC2-01-C7). The designs of both trials were almost
identical (Figure 2), each including a screening and 8-week
treatment period with application of topical agent once daily.
Due to difference in formulation and packaging, the trials were
investigator blinded. Numerous precautions were taken to
ensure that this blinding was kept throughout the trials. The trial
populations consisted of male and female subjects, above the age
of 18 years, with mild-to-moderate psoriasis according to PGA
and with a treatment area of 2%–30% of the body (trunk and/or
limbs). Baseline-modified PASI was required to be at least 2 in
trial MC2-01-C2 and at least 3 in trial MC2-01-C7. Subjects
were randomly allocated to one of three parallel treatment
groups in a 3 : 1 : 3 ratio (CAL/BDP PAD-cream, marketed
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Figure 2 Phase 3 trial design. Two prospective, investigational, investigator-blind, vehicle and active-controlled, parallel-group, threearm, randomized, phase 3 trials enrolled 1286 subjects at multiple sites in the United States of America (MC2-01-C2; NCT03308799;
N = 796) and the European Union (MC2-01-C7; NCT03802344; N = 490). The trial designs of the trials were almost identical, each including a screening and 8-week treatment period with application interval once daily. The trial populations consisted of male and female subjects, above the age of 18 years, with mild-to-moderate psoriasis according to PGA and with a treatment area of 2%–30% of the body
(trunk and/or limbs). Baseline mPASI was required to be at least 2 in trial MC2-01-C2 and at least 3 in trial MC2-01-C7. Subjects were
randomly allocated to one of three parallel treatment groups in a 3 : 1 : 3 ratio.

under the brand name Wynzoraâ Cream); cream vehicle and
active comparator [a marketed CAL/BDP gel/topical suspension
under brand names Taclonexâ Topical Suspension (LEO Laboratories Ltd., Dublin 12, Ireland) and Dovobetâ/Daivobetâ Gel
(EU and other territories)]. Randomization was performed using
a validated system that automated the random assignment of
treatment groups to randomization numbers. Treatment assignment was performed via a central interactive web response system (IWRS) in accordance with a pre-planned computergenerated randomization schedule and was stratified by trial site
and country to ensure proper distribution into the three treatment arms. Subjects were at the sites instructed to topically
apply their assigned product to the affected area(s) on the trunk
(including the neck), limbs (i.e. arms, including the back of the
hands) and legs (including the buttocks and the top of the feet),
once daily for 8 weeks. The patient should apply sufficient product to treat the entire affected areas and rub in gently to ensure
that the plaques were saturated with the medication. The patient
should not apply product to the face, genital area or intertriginous areas. In the MC2-01-C7 trial, scalp psoriasis was treated,
but disease severity or treatment efficacy on the scalp was not
part of the PGA score reported in this publication.
Study assessments

Efficacy and safety assessments were carried out at baseline and
at Week 1, Week 4, Week 6 and Week 8. The primary objective
of the pooled analysis was to evaluate the efficacy of CAL/BDP
PAD-cream compared to active comparator, and the secondary
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objective was to characterize the safety profile CAL/BDP PADcream, the active comparator and the vehicle.
Prespecified selected efficacy end point variables included: (i)
the proportion of patients in each treatment group with ‘physician’s global assessment (PGA) treatment success’ [defined as a
PGA score of 0 (clear) or 1 (almost clear) and with a minimum
2 points improvement from Baseline]; (ii) the percentage change
in modified (excluding the head) Psoriasis Area and Severity
Index (mPASI) score and the proportion of subjects with
mPASI75 (at least 75% reduction in mPASI from Baseline); (iii)
improvement in Dermatology Life Quality Index (DLQI) and
(iv) patients’ assessment of treatment acceptability using a Psoriasis Treatment Convenience Scale (PTCS) calculated as the sum
of five treatment-specific questions rated on a 1–10 scale. The
PTCS also included an additional question to assess overall satisfaction with treatment.
Statistical analyses

Following the completion of the two phase 3 trials, the present
pooled analyses were based on the combined data set and on primary and secondary end points defined in the two phase 3 trials.
Efficacy analyses were based on the modified intention-to-treat
(MITT) population (n = 1271), which included all subjects randomly assigned to any investigational product, treated with the
assigned investigational product and who had at least one assessment of efficacy after starting treatment. Safety analyses included
all randomized subjects opening the medication (n = 1283).
Under the assumptions made for sample size calculation, the
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two phase 3 trials had minimum 90% power to demonstrate
superiority of CAL/BDP PAD cream comparison to vehicle.
Efficacy end points were analysed following a treatment policy
strategy using all available data regardless of treatment and treatment adherence and imputing missing data by multiple imputation. For the PTCS end point, a while-on-treatment strategy was
used requiring that treatment was followed within 7 days of the
assessment.
Superiority analyses for end points (PGA treatment success,
mPASI75, DLQI ‘satisfaction’ score 0 or 1) were analysed using
a logistic model with effects of treatment, study and the baseline
value of the end point as factors. Superiority analyses for continuous end points (mPASI, PTCS and DLQI) were performed
using an ANCOVA model including treatment, study and baseline PGA as factors, and the baseline value of the respective end
point as covariate. Efficacy and safety end points were summarized by frequency and severity for each treatment group. Analyses were performed using SAS version 9.3 (SAS Institute Inc.,
Cary, NC, USA).

Results
Subject disposition, demographics and baseline
characteristics

The MITT set included all subjects treated with CAL/BDP PADcream, the active comparator or the vehicle (n = 1271). Overall,
551 patients were randomized to treatment with CAL/BDP
PAD-cream, 542 patients were randomized to treatment with
active comparator and 178 patients were randomized to treatment with vehicle. Of the randomized patients, 526 (94.6%), 513
(93.8%) and 149 (81.4%) completed the trial in the three groups
respectively (Table 1).
Baseline demographics and disease characteristics were comparable across the treatment arms (Tables 1 and 2). At baseline,
228 (17.9%) and 1043 (82.1%) patients had mild and moderate
disease, respectively, according to PGA of disease severity.
Three-hundred and twenty-one (25.3%) subjects had at least
moderate disease, defined as BSA > 10%.

Efﬁcacy
PGA treatment success The percentage of subjects achieving

PGA treatment success at Week 8 was statistically significantly
higher in the CAL/BDP PAD-cream group (43.2%) compared to
the vehicle group (5.2%; P < 0.0001) and to the CAL/BDP TS
group (31.9%; P < 0.0001). Moreover, statistically significant
differentiation between CAL/BDP PAD-cream and CAL/BDP TS
was observed as early as Week 4 (P = 0.0001) and maintained
up to Week 8 (Figure 3a). PGA treatment success with CAL/
BDP PAD-cream for subjects with BSA ≤ 10 and >10 was 41.7%
and 48.3%, respectively, while the corresponding data for CAL/
BDP TS were 33.0% and 28.7% (Table 3), demonstrating that
the efficacy of CAL/BDP PAD-cream is maintained or even
improves as baseline severity increases, while CAL/BDP TS loses
efficacy as baseline severity increases. Figure 4 displays the
results of a subject who underwent an 8-week, once-daily regimen of CAL/BDP PAD-cream application on the psoriatic skin
of the elbows.
Change from Baseline in mPASI The mean per cent reduction
in mPASI score from baseline to Week 8 was statistically greater
for CAL/BDP PAD-cream (64.6%) than CAL/BDP TS (56.4%;
P < 0.0001) and vehicle (20.0%; P < 0.0001). The difference in
treatment effect between CAL/BDP PAD-cream and CAL/BDP
TS was statistically significant as early as Week 1 (P = 0.0009)
and maintained at Weeks 4 (P < 0.0001) and 6 (P < 0.0001; Figure 3b). In addition, the proportion of subjects obtaining
mPASI75 was greater in the CAL/BDP PAD-cream group than
in the CAL/BDP TS group at Week 4 (22.1% vs. 13.7%;
P = 0.0004) and at Week 8 (44.3% vs. 34.5%; P = 0.0011; Figure 3c). mPASI75 with CAL/BDP PAD-cream for subjects with
BSA ≤ 10 and >10 was 43.6%, and 46.5%, respectively, while the
corresponding data for CAL/BDP TS were 35.2% and 32.5%.
Improvement in Dermatology quality life index (DLQI) The
mean DLQI improvement from baseline, at Week 8, was significantly greater for CAL/BDP PAD-cream (6.5 points) compared

Table 1 The modiﬁed intention-to-treat (MITT) set included all subjects randomly assigned to any investigational product, treated with
the assigned investigational product and who had at least one assessment of efﬁcacy after starting treatment
CAL/BDP PAD-cream
N = 551

Active comparator
N = 542

Cream vehicle
N = 178

Total randomized
N = 1271

Number of subjects randomized

556

547

183

1286

Number of subjects treated with an investigational drug
(safety set)

555

546

182

1283

Number of subjects in modiﬁed intention to treat

551

542

178

1271

Number of subjects prematurely discontinued trial, n (%)

30 (5.4)

34 (6.2)

24 (18.6)

98 (7.6)

Number of subjects completed trial, n (%)

526 (95.5)

513 (94.6)

149 (83.7)

1188 (93.5)

‘CAL/BDP PAD-cream’ represents patients treated with a ﬁxed dose of calcipotriene and betamethasone dipropionate topical cream, ‘Active Comparator’ represents patients treated with a ﬁxed dose of calcipotriene and betamethasone dipropionate topical suspension/gel and ‘Cream Vehicle’ represents patients
treated with a topical cream comprised of inactive ingredients identical to CAL/BDP PAD-cream.
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Table 2 The modiﬁed intention-to-treat (MITT) population included all subjects randomly assigned to any investigational product, treated
with the assigned investigational product and who had at least one assessment of efﬁcacy after starting treatment
CAL/BDP PAD-cream
N = 551

CAL/BDP TS
N = 542

Cream vehicle
N = 178

Total
N = 1271

MC2-01-C2

338 (61.3)

334 (61.6)

112 (62.9)

784 (61.7)

MC2-01-C7

213 (38.7)

208 (38.4)

66 (37.1)

487 (38.3)

338 (61.3)

334 (61.6)

112 (62.9)

784 (61.7)

94 (17.1)

90 (16.6)

28 (15.7)

212 (16.7)

Study, n (%)

Country, n (%)
USA
Germany
Czech Republic

64 (11.6)

63 (11.6)

20 (11.2)

147 (11.6)

Poland

55 (10.0)

55 (10.1)

18 (10.1)

128 (10.1)

Female

214 (38.8)

209 (38.6)

65 (36.5)

488 (38.4)

Male

337 (61.2)

333 (61.4)

113 (63.5)

783 (61.6)

456 (82.8)

434 (80.1)

145 (81.5)

1035 (81.4)

95 (17.2)

108 (19.9)

33 (18.5)

236 (18.6)
1161 (91.3)

Sex, n (%)

Age, n (%)
18–64 years
65 years or more
Race, n (%)
White

498 (90.4)

500 (92.3)

163 (91.6)

Black or African American

34 (6.2)

20 (3.7)

12 (6.7)

66 (5.2)

Other

19 (3.4)

22 (4.1)

3 (1.7)

44 (3.5)

Ethnic origin, n (%)
Hispanic or latino
Not hispanic or latino

99 (18.0)

91 (16.8)

30 (16.9)

220 (17.3)

452 (82.0)

451 (83.2)

148 (83.1)

1051 (82.7)

PGA, n (%)
Mild (2)

105 (19.1)

91 (16.8)

32 (18.0)

228 (17.9)

Moderate (3)

445 (80.8)

451 (83.2)

145 (81.5)

1043 (82.1)

Severe (4)

1 (0.2)†

1 (0.6)

BSA, n (%)
Less or equal 10%

422 (76.6)

396 (73.1)

132 (74.2)

950 (74.7)

More than 10%

129 (23.4)

146 (26.9)

46 (25.8)

321 (25.3)

BSA, Body surface area, PGA, Physician’s global assessment.
‘CAL/BDP PAD-cream’ represents patients treated with a ﬁxed dose of calcipotriene and betamethasone dipropionate topical cream, ‘CAL/BDP TS’ represents patients treated with a ﬁxed dose of calcipotriene and betamethasone dipropionate topical suspension/gel and ‘Cream Vehicle’ represents patients treated with a topical cream comprised of inactive ingredients identical to CAL/BDP PAD-cream.
†
Two subjects with severe psoriasis was by mistake included in the trials. These subjects were categorized as moderate in all calculations.

to CAL/BDP TS (5.6 points, P < 0.0001) and vehicle (2.5
points, P < 0.0001). A statistically significant difference
between CAL/BDP PAD-cream and CAL/BDP TS was also
observed at Week 4 (P = 0.0002; Figure 5). A DLQI score of 0
or 1 (meaning that the psoriasis disease had no effect at all on
patient’s life) at Week 8 was obtained by 43.8% in the CAL/BDP
PAD-cream group and 34.2% in the CAL/BDP TS group
(P = 0.0005).
Improvement in Psoriasis Treatment Convenience Score
(PTCS) The mean psoriasis treatment convenience score

(PTCS) at Week 8 for CAL/BDP PAD-cream (40.4) was statistically significantly greater than CAL/BDP TS (37.0; P < 0.0001).
Similar significant level between CAL/BDP PAD-cream and
CAL/BDP TS was seen at Week 1 and Week 4. Review of the
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individual responses to the PTCS questions made clear that the
greater preference for CAL/BDP PAD-cream was mainly due to
CAL/BDP TS being a greasier formulation. Finally, the sixth
question ‘Overall, how satisfied were you with the medical treatment’ was highly significant in favour of CAL/BDP PAD-cream
compared to the topical suspension (P < 0.0001).
Safety

There were no statistically significant differences between the
treatment arms in relation to the proportion of subjects experiencing a TEAE. Adverse drug reactions during the trial were seen
in 4.1%, 2.6% and 6.6% of subjects in the CAL/BDP PAD-cream
arm, the CAL/BDP TS arm and the vehicle arm respectively
(Table 4). The highest frequency of adverse drug reactions was
in System Organ Class Preferred Term ‘General disorders and
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(a)
% PGA treatment success

50

P <0.0001
P <0.0001

40
30

P <0.0001

Table 3 CAL/BDP PAD-cream represents patients treated with a
ﬁxed dose of calcipotriene and betamethasone dipropionate topical cream, ‘CAL/BDP TS’ represents patients treated with a ﬁxed
dose of calcipotriene and betamethasone dipropionate topical
suspension/gel and ‘Cream Vehicle’ represents patients treated
with a topical cream comprised of inactive ingredients identical to
CAL/BDP PAD-cream
CAL/BDP PAD-cream
N = 551

20
10

All, n (%)

0
0

2

4

6

8

551 (43.2)
(0.391, 0.474)
PGA severity, n (%)
Mild

Weeks
mPASI, % change from baseline

(b)
70

P <0.0001

60

P <0.0001

BSA ≤ 10%

40
P = 0.0009

30

BSA > 10%,
n (%)

20
10
0
0

2

4

6

8

(c)
50

P = 0.0011

40
% m PASI 75

Cream Vehicle
N = 178

542 (31.9)
178 (5.2)
(0.279, 0.359) (0.017, 0.082)

105 (10.6)
(0.047, 0.166)
446 (50.9)
(0.462, 0.556)

91 (15.6)
32 (0.0)
(0.081, 0.231)
451 (35.2)
146 (6.3)
(0.306, 0.397) (0.021, 0.106)

422 (41.7)
(0.369, 0.465)
129 (48.3)
(0.395, 0.570)

396 (33.0)
(0.283, 0.378)
146 (28.7)
(0.211, 0.363)

BSA severity

50

Weeks

132 (4.5)
(0.006, 0.083)
46 (7.3)
( 0.006, 0.151)

BSA, Body surface area; PGA, Physician’s global assessment; mPASI, Modiﬁed psoriasis area and severity index.
95% Conﬁdence intervals in parentheses. The signiﬁcance level for comparison of CAL/BDP PAD-cream to CAL/BDP TS was P < 0.0001 for patients
with moderate Baseline PGA. No statistical difference was observed
between the two active treatments for mild patients. The signiﬁcance level for
comparison of CAL/BDP PAD-cream to CAL/BDP TS was P = 0.0044 for
patients with baseline BSA ≤ 10% and P = 0.0012 for patients with baseline
BSA > 10%.

P <0.0001

30

A total of 26 (2.0%) subjects reported a serious adverse event
with similar frequency in the three treatment groups. None was
assessed by the investigator to be related to trial medication.
Laboratory data did not suggest CAL-mediated changes in calcium metabolism in any of the three arms during the trial.

P = 0.0004

20
10
0
0

2

4

6

8

Weeks

Figure 3 (a) Proportion of patients obtaining PGA treatment success improvement by trial visit. (b) Percentage change in mPASI
from baseline. (c) Proportion of patients obtaining mPASI75 by trial
visit. A response to active treatment could already be noted after
1 week. All data based on the MITT population using multiple
imputation.

administration site conditions’, but there were no local site reactions above 1%. In the CAL/BDP PAD-cream arm, the most frequent local site reactions were application site pain, irritation,
and pruritus, each with a frequency of 0.7%.
There were 15 AEs reported in 9 subjects leading to discontinuation. In the CAL/BDP PAD-cream group, three (0.5%) subjects were discontinued due to AEs with two events (insomnia
and urticaria) deemed to be probably related, whereas the third
event (renal cell carcinoma) was deemed unrelated.
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Moderate

P <0.0001

CAL/BDP TS
N = 542

Discussion
Results from the present meta-analysis of pooled data from two
randomized, controlled phase 3 trials investigating the efficacy
and safety of CAL/BDP PAD-cream for the topical treatment of
psoriasis demonstrated superiority in comparison to CAL/BDP
TS for all efficacy end points including PGA treatment success,
mPASI and PASI75. Superiority was also demonstrated for
patient-reported DLQI and PTCS.
Overall, these trials demonstrated that CAL/BDP PAD-cream
was significantly more effective than CAL/BDP TS after 8 weeks
of once-daily use. The achievement of PGA treatment success at
Week 8 was greater for CAL/BDP PAD-cream (43.2%) than for
CAL/BDP TS (31.9%) (P < 0.0001), and the reduction in
mPASI from baseline to Week 8 was greater for CAL/BDP PADcream (64.6%) compared to CAL/BDP TS (56.4%; P < 0.0001).
These findings were confirmed by significantly more subjects
obtaining mPASI75 at Week 8 in the CAL/BDP PAD-cream
group than in the CAL/BDP TS (44.3% vs. 34.5%, respectively).
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Figure 4 Images depict an adult female with psoriasis vulgaris on the elbows, at baseline and after a 1, 4, 6 and 8 weeks of once-daily
application of CAL/BDP PAD-cream.
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Cahnge in DLQI from baseline

The CAL/BDP PAD-cream had a faster onset of action than
CAL/BDP TS. With respect to treatment efficacy measured by
reduction in mPASI, there was a statistically significant difference in favour of CAL/BDP PAD-cream already at Week 1
(mean percentage reduction: 25.5% vs. 20.5%, P = 0.0009),
which continued with significant difference at all subsequent visits (P < 0.0001).
PGA treatment success at week 8 in subjects using CAL/BPD
cream with BSA >10% increased to 48.3% (compared to 43.2%
in subjects with <10% BSA), while PGA treatment success at
week 8 for CAL/BDP TS subjects with >10% BSA decreased to
28.7% (compared to 31.9% in subjects with <10% BSA).
For subjects with BSA > 10% treated with CAL/BDP PADcream, mPASI75 increased from 44.3% to 46.5%, whereas efficacy of CAL/BDP TS decreased from 34.5% to 32.5%. The
increase in treatment efficacy in subjects with BSA > 10% treated with CAL/BDP PAD-cream was seen for all efficacy parameters including mPASI and DLQI, whereas a decrease was seen for
subjects treated with CAL/BDP TS.
At all visits throughout the trial, patient assessed QoL was
higher in patients having received CAL/BDP PAD-cream than in
those treated with the CAL/BDP TS. A significantly greater proportion of subjects treated with CAL/BDP PAD-cream reported
that the psoriasis had no effect at all on their life (DLQI 0 or 1)
compared to CAL/BDP TS (43.8% vs. 34.2%, P = 0.0005) after
8 weeks of treatment.
Types and incidences of AEs were on par with the safety profile of currently available CAL/BDP products. The majority of
adverse drug reactions were local site reactions, with no adverse
drug reaction reported at a frequency >1%.

2

Weeks
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8

0
-2
-4
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P = 0.0002
P <0.0001

-8

Figure 5 DLQI improvement by trial visit. Data based on the MITT
population using multiple imputation.

Topical fixed dose combinations of CAL and BDP have in the
last 20 years proven very effective and safe both for acute treatment and for long-term maintenance therapy. However, until
now CAL/BDP combination products have been restricted to
non-aqueous oil- or paraffin-based formulations resulting in
formulations that by many are perceived as greasy or sticky.
Such formulations take a long time to dry, interfere with clothing and other daily activities. The result can for many patients
be lack of adherence to treatment leading to suboptimal treatment outcomes in the real-world setting.17,18
The robust oil-in-water dispersion structure resulting from
the PADTM Technology eliminated the inherent lack of CAL/BDP
stability in water. In addition, PADTM Technology creams offer
unique advantages with respect to solubility of actives and high
penetration into the skin. The physical appearance of the CAL/
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Table 4 CAL/BDP PAD-cream represents patients treated with a ﬁxed dose of calcipotriene and betamethasone dipropionate topical
cream, ‘CAL/BDP TS’ represents patients treated with a ﬁxed dose of calcipotriene and betamethasone dipropionate topical suspension/
gel and ‘Cream Vehicle’ represents patients treated with a topical cream comprised of inactive ingredients identical to CAL/BDP PADcream

Subjects with any adverse drug reactions, n (%)

CAL/BDP PAD-cream
N = 555

CAL/BDP TS
N = 546

Cream Vehicle
N = 182
12 (6.6)

23 (4.1)

14 (2.6)

Adverse drug reactions leading to discontinuation of trial regime, n (%)

3 (0.5)

5 (0.9)

7 (3.8)

Drug-related serious adverse events, n (%)

0 (0.0)

0 (0.0)

0 (0.0)

System Organ Class (Preferred Term)
General disorders and administration site conditions

15 (2.7)

8 (1.5)

7 (3.8)

Application site dermatitis

0 (0.0)

2 (0.4)

1 (0.5)

Application site eczema

1 (0.2)

0 (0.0)

0 (0.0)

Application site erosion

2 (0.4)

0 (0.0)

2 (1.1)

Application site exfoliation

1 (0.2)

0 (0.0)

0 (0.0)

Application site hypersensitivity

0 (0.0)

0 (0.0)

1 (0.5)

Application site irritation

4 (0.7)

0 (0.0)

1 (0.5)

Application site pain

4 (0.7)

1 (0.2)

1 (0.5)

Application site pruritus

4 (0.7)

4 (0.7)

1 (0.5)

Application site telangiectasia

1 (0.2)

0 (0.0)

0 (0.0)

Application site vesicles

0 (0.0)

1 (0.2)

0 (0.0)

Infections and infestations

2 (0.4)

4 (0.7)

1 (0.5)

Application site folliculitis

2 (0.4)

1 (0.2)

0 (0.0)

Herpes zoster

0 (0.0)

1 (0.2)

0 (0.0)

Nasal abscess

0 (0.0)

1 (0.2)

0 (0.0)

Upper respiratory tract infection

0 (0.0)

1 (0.2)

1 (0.5)

0 (0.0)

0 (0.0)

1 (0.5)

Injury, poisoning and procedural complications
Overdose

0 (0.0)

0 (0.0)

1 (0.5)

Investigations

1 (0.2)

2 (0.4)

2 (1.1)

Blood parathyroid hormone increased

1 (0.2)

2 (0.4)

2 (1.1)

1 (0.2)

1 (0.2)

0 (0.0)

Dysgeusia

0 (0.0)

1 (0.2)

0 (0.0)

Headache

1 (0.2)

0 (0.0)

0 (0.0)

1 (0.2)

0 (0.0)

0 (0.0)

Nervous system disorders

Psychiatric disorders
Insomnia
Skin and subcutaneous tissue disorders

1 (0.2)

0 (0.0)

0 (0.0)

4 (0.7)

1 (0.2)

2 (1.1)

Dermatitis contact

0 (0.0)

1 (0.2)

0 (0.0)

Pruritus

1 (0.2)

0 (0.0)

0 (0.0)

Psoriasis

0 (0.0)

0 (0.0)

2 (1.1)

Rash

1 (0.2)

0 (0.0)

0 (0.0)

Skin erosion

1 (0.2)

0 (0.0)

0 (0.0)

Urticaria

1 (0.2)

0 (0.0)

0 (0.0)

TEAE, Treatment-emergent adverse events.

BDP PAD-cream is a white, easily spreadable cream that absorbs
rapidly and completely into the skin leaving no sticky feeling
behind.
The increased patient acceptability of the CAL/BDP PADcream is demonstrated by the significantly increased treatment
preference (PTCS) at Week 8 compared to the CAL/BDP TS. A
similar statistically significant difference between CAL/BDP
PAD-cream and CAL/BDP TS was observed at Week 1 and
Week 4. Analysis of single treatment acceptability questions
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clarified that the higher preference for CAL/BDP PAD-cream
was mainly due to the cream being a less greasy formulation
than to CAL/BDP TS.
As previous studies have demonstrated that treatment adherence is affected by greasy or oily, sticky topical products that
stain clothes or are difficult to apply,16,17 factors related to physical characteristics of the topical product are of importance for
the level of adherence of the medication.19,20 An important benefit of the PADTM Technology formulation is its resulting high
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penetration/efficacy profile, which presumably have contributed
to the superior treatment efficacy of CAL/BDP PAD-cream compared to CAL/BDP TS.
The CAL/BDP fixed combination is approved and marketed
in three formulations worldwide, and the combination of CAL/
BDP is recommended as first-line treatment by disease management guidelines in Europe, Canada and in the US.5–8,10,21 In the
recently published AAD-NFP Guidelines,8 there is a class A recommendation of use of CAL/BDP products for psoriasis up to
52 weeks. Furthermore, this guideline emphasizes the importance of selecting topical formulations accepted and preferred by
the patient. This is in line with the conclusion in a 2016 consensus paper22 that a key research priority for topical psoriasis therapy is to develop agents with higher efficacy, fewer side-effects
and potential for long-term use. Limitations of this pooled analysis are missing data on scalp psoriasis, prolonged efficacy after
intermittent use as well as data on efficacy and safety in adolescent patients with CAL/BDP PAD-cream. For these purposes,
further data should be collected.

Conclusions
The present analysis of pooled data from two randomized, controlled phase 3 trials investigating the efficacy and safety of a
CAL/BDP PAD-cream for the topical treatment of psoriasis
demonstrated statistically significant efficacy in favour of CAL/
BDP PAD-cream for all efficacy end points including PGA treatment success, mPASI and PASI75. Superiority was also demonstrated for patient-reported dermatology life quality index and
treatment preference. Based on this unique combination of high
efficacy combined with favourable safety and excellent treatment
preference in a single product, CAL/BDP PAD-cream can be
considered a first-line topical therapy of psoriasis.
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